Patricia Myers

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised Confluent, a data-streaming platform pioneering a fundamentally new category of data infrastructure that sets data in motion, on its acquisition of WarpStream, an Apache Kafka-compatible data-streaming platform.

Cooley advised Reverence Capital Partners’ portfolio company Transact Campus, an innovative campus technology and payment solutions company, on a definitive agreement signed by Reverence Capital Partners to sell Transact to Roper Technologies for $1.6 billion.

Cooley advised Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein-coupled receptor (GPCR)-targeted radiopharmaceuticals to treat a broad range of solid tumors, on the formation of a strategic agreement with Eli Lilly to take forward Radionetics’ proprietary GPCR-targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million up-front cash payment. Additionally, Lilly obtained the exclusive right to acquire Radionetics for $1 billion upon conclusion of an exercise period.

Cooley advised CareJourney, a preeminent provider of clinically relevant healthcare data and artificial intelligence-powered analytics and insights, on its acquisition by Arcadia, a top data platform for healthcare.